JP2015511957A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511957A5
JP2015511957A5 JP2014560367A JP2014560367A JP2015511957A5 JP 2015511957 A5 JP2015511957 A5 JP 2015511957A5 JP 2014560367 A JP2014560367 A JP 2014560367A JP 2014560367 A JP2014560367 A JP 2014560367A JP 2015511957 A5 JP2015511957 A5 JP 2015511957A5
Authority
JP
Japan
Prior art keywords
salt
ethoxy
arginine
phosphonoethoxy
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511957A (ja
JP6325986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/054548 external-priority patent/WO2013131985A1/en
Publication of JP2015511957A publication Critical patent/JP2015511957A/ja
Publication of JP2015511957A5 publication Critical patent/JP2015511957A5/ja
Application granted granted Critical
Publication of JP6325986B2 publication Critical patent/JP6325986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560367A 2012-03-07 2013-03-07 免疫学的に有用なアルギニン塩 Active JP6325986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
US61/608,011 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (3)

Publication Number Publication Date
JP2015511957A JP2015511957A (ja) 2015-04-23
JP2015511957A5 true JP2015511957A5 (cg-RX-API-DMAC7.html) 2016-04-28
JP6325986B2 JP6325986B2 (ja) 2018-05-16

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560367A Active JP6325986B2 (ja) 2012-03-07 2013-03-07 免疫学的に有用なアルギニン塩

Country Status (18)

Country Link
US (1) US9320748B2 (cg-RX-API-DMAC7.html)
EP (1) EP2822947B1 (cg-RX-API-DMAC7.html)
JP (1) JP6325986B2 (cg-RX-API-DMAC7.html)
CN (1) CN104203946B (cg-RX-API-DMAC7.html)
AU (1) AU2013229466A1 (cg-RX-API-DMAC7.html)
CA (1) CA2865759C (cg-RX-API-DMAC7.html)
CY (1) CY1118091T1 (cg-RX-API-DMAC7.html)
DK (1) DK2822947T3 (cg-RX-API-DMAC7.html)
ES (1) ES2597755T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161354T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030175T2 (cg-RX-API-DMAC7.html)
LT (1) LT2822947T (cg-RX-API-DMAC7.html)
MX (1) MX346678B (cg-RX-API-DMAC7.html)
PL (1) PL2822947T3 (cg-RX-API-DMAC7.html)
PT (1) PT2822947T (cg-RX-API-DMAC7.html)
RU (1) RU2014140336A (cg-RX-API-DMAC7.html)
SI (1) SI2822947T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013131985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
JP6894237B2 (ja) 2014-03-26 2021-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 変異体ブドウ球菌抗原
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US20230110516A1 (en) * 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU695769B2 (en) 1994-07-01 1998-08-20 Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Helicobacter proteins and vaccines
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2003049762A2 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP2353608B1 (en) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
CA2608278A1 (en) 2005-05-12 2006-12-28 Guido Grandi Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
ES2565377T3 (es) 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
CN102481354A (zh) 2009-06-01 2012-05-30 诺华有限公司 肺炎球菌RrgB分化枝的组合物
AU2010258677B2 (en) * 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2013030378A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Similar Documents

Publication Publication Date Title
JP2015511957A5 (cg-RX-API-DMAC7.html)
JP2013534248A5 (cg-RX-API-DMAC7.html)
CN112469713A (zh) 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
RU2014140336A (ru) Иммунологически полезные соли аргинина
JP2013515742A5 (cg-RX-API-DMAC7.html)
JP2014525429A5 (cg-RX-API-DMAC7.html)
JP2018531941A5 (cg-RX-API-DMAC7.html)
JP2014051497A5 (cg-RX-API-DMAC7.html)
JP2008542286A5 (cg-RX-API-DMAC7.html)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
WO2015017821A3 (en) Therapeutically active compounds and their methods of use
JP2013542919A5 (cg-RX-API-DMAC7.html)
JP2016532722A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP2016531894A5 (cg-RX-API-DMAC7.html)
JP2014513123A5 (cg-RX-API-DMAC7.html)
JP2016516074A5 (cg-RX-API-DMAC7.html)
BR112013003439A2 (pt) "inibidores de oxadiazol de produção de leucotrieno"
JP2014218522A5 (cg-RX-API-DMAC7.html)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2012513416A5 (cg-RX-API-DMAC7.html)
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
JP2015522037A5 (cg-RX-API-DMAC7.html)